Analytical Data
-
Gene name
CRBN
- Application
-
Species
Human
-
Source
Baculovirus
-
Tag
C- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q96SW2
-
Expression Region
1-442aa
-
Molecular Weight
53.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CRBN (Cereblon) is an E3 ubiquitin ligase associated with various cellular processes, including protein degradation, signal transduction, and development. It has gained significant attention in recent years due to its critical role in the mechanism of action of thalidomide and its derivatives, which are used in the treatment of multiple myeloma and other conditions. These compounds bind to CRBN, promoting the ubiquitination and subsequent degradation of specific substrate proteins, leading to antitumor effects. The understanding of CRBN's function and substrate specificity is crucial for the development of novel therapeutics and optimizing existing drug efficacy. Recent studies have explored the structural and functional mechanisms of CRBN, revealing its interaction with various substrates and the impact of mutations on its activity. Researchers are increasingly focused on harnessing CRBN's ubiquitin ligase activity for targeted protein degradation in cancer therapy and other diseases. This research aims to unveil CRBN's potential beyond its canonical roles, such as identifying new therapeutic targets and improving drug design strategies. Overall, the study of CRBN and its associated pathways is pivotal in advancing cancer treatment and understanding fundamental biological processes.
